Check out your Company Bowl for anonymous work chats.
Looking forward to presenting our podium and posters at #ISPOREurope in November - hope to see you there!
Boston/US Roles: Director, Health Analytic Solutions Principal Analyst, Health Analytic Solutions Director of Business Development Senior Software Engineer- Data Science EU Roles: Principal Analyst, Health Analytic Solutions Senior Analyst, Health Analytic Solutions
Panalgo - Career Page
Looking forward to presenting our podium and posters at #ISPOREurope in November - hope to see you there!
BHE is now Panalgo! We’re thrilled to announce our new brand - read our press release to find out more about why we changed our name and how we chose Panalgo, and be sure to check out our new website panalgo.com
BHE Announces Rebrand to Panalgo, Continues Its Mission of Leadership in Analytics Software for Healthcare
Over 35,000 COVID-19 research papers have been published since January, Joe Menzin weighs the risks and rewards of fast tracked studies in Health IT Outcomes.
The Pressure To Publish Rapidly: The Risks Vs. Rewards Of Fast-Tracked COVID-19 Studies
In our latest blog Stephen Johnston, PhD and Eric Ammann from Johnson and Johnson share how they measured the economic burden of CRC complications from both a payer and provider perspective using #RWD and our IHD software analytics.
Using RWD & Analytics to Measure the Economic Burden of Colorectal Cancer Complications - BHE Analytics Roundup
Excited to have industry leaders Peter Neumann and Samy Suissa join our newly formed Strategic Advisory Board.
BHE Announces Formation of Strategic Advisory Board
Do you have a passion for transforming healthcare with sophisticated analytics? Check out these roles.
Join us June 25th as we share results from our Industry Benchmark Survey on the state of analytics in life sciences
[Webinar] State of Data Analytics and Machine Learning in the Life Sciences Industry: 2020 Benchmarking Survey
In a recent Pharmacy Times article Matthew Sussman weighs the risks and rewards of value-based drug evaluations during a pandemic.
Pandemic Pricing: The Risks and Rewards of Fast-Tracking Value-Based Drug Evaluations